1-20 of 150
Susan M. O'Brien, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Adrian Wiestner, MD PhD, Paolo Ghia, MD PhD, John C. Byrd, MD, Inhye E Ahn, MD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Daniel Jones, MD PhD, Leo W. K. Cheung, PhD, Elizabeth Chong, PhD, Kevin Kwei, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jennifer A. Woyach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-134386
Published: 2020
Journal Articles

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Mariela Sivina, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Philip A. Thompson, MB, MS, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-141014
Published: 2020
Journal Articles

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

John N. Allan, MD, Tait Shanafelt, MD, Adrian Wiestner, MD PhD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Esteban Braggio, PhD, Emily Liu, MS, James P. Dean, MD PhD, Dominic Lai, PharmD, Inhye E. Ahn, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-134431
Published: 2020
Journal Articles

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Kiyomi Morita, MDPhD, Koji Sasaki, MD, Guillaume Richard-Carpentier, MD, Marina Konopleva, MD PhD, Xuelin Huang, PhD, Nicholas J. Short, MD, Nitin Jain, MD, Farhad Ravandi, MBBS, Bouthaina S. Dabaja, MD, Naval Daver, MD, Tapan M. Kadia, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSCE, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD PhD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Richard E. Champlin, MD, Issa F. Khouri, MD, Partow Kebriaei, MD, Heather M. Schroeder, Maria Khouri, Koichi Takahashi, MD PhD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142121
Published: 2020
Journal Articles

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Elias Jabbour, MD, Nitin Jain, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Jan A. Burger, MD PhD, William G. Wierda, MD PhD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Nicholas J. Short, MD, Stefan Faderl, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Steven M. Kornblau, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Philip A. Thompson, MB, MS, Joseph D. Khoury, MD, Hayley Balkin, Mary Kelly, Hind Azzawi, Rebecca Garris, MSc, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–39.
https://doi.org/10.1182/blood-2020-136873
Published: 2020
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Naval Daver, MD, Hind Rafei, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Maria R Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-139896
Published: 2020
Journal Articles

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Hind Rafei, MD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Maria Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-140037
Published: 2020
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Yesid Alvarado, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Serena Chew, PharmD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Maria Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-143386
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-143286
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

Hua-Jay J Cherng, MD, Nadya Jammal, PharmD, Shilpa Paul, PharmD, Xuemei Wang, MS, Koji Sasaki, MD, Philip A. Thompson, MB, MS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD, Nitin Jain, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-135938
Published: 2020
Journal Articles

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Rashmi Kanagal-Shamanna, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Nicholas J. Short, MD, C. Cameron Yin, MD PhD, Keyur Patel, MD PhD, Sanam Loghavi, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Susan M. O'Brien, MD, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–43.
https://doi.org/10.1182/blood-2020-142012
Published: 2020
Journal Articles

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Nitin Jain, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Yesid Alvarado, MD, Jan A. Burger, MD PhD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Steven M. Kornblau, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Monica Kwari, BSN, Caitlin R. Rausch, PharmD, Christopher Loiselle, BS, Anna Milton, Juan Rivera, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-138569
Published: 2020
Journal Articles

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Dan Nichols, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Prithviraj Bose, MD, Rita Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–25.
https://doi.org/10.1182/blood-2020-143400
Published: 2020
Journal Articles

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

Rajat Bannerji, MDPhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Susan M. O'Brien, MD, Johannes Duell, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Jingjin Li, PhD, Dina M. Flink, PhD, Min Zhu, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Max S. Topp, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136659
Published: 2020
Journal Articles

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Philip A. Thompson, MB, MS, Yesid Alvarado, MD, Nitin Jain, MD, Musa Yilmaz, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Steven M. Kornblau, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Heather M Schroeder, Monica Kwari, BSN, Shilpa Paul, PharmD, Benjamin Nwakanme, Christopher Loiselle, BS, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–11.
https://doi.org/10.1182/blood-2020-138565
Published: 2020
Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, MD PhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jeffrey A. Barnes, MD PhD, Stephen M Ansell, MD PhD, Susan M. O'Brien, MD, Julio Chavez, Johannes Duell, MD, Kevin A. David, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Robert Charnas, PhD, Srikanth R. Ambati, MBBS, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Min Zhu, PhD, Jingjin Li, PhD, Peter Gasparini, MS, Anfal Ibrahim, BS, Vladimir Jankovic, MD, Nathalie Fiaschi, PhD, Olulanu Aina, PhD, Wen Zhang, PhD, Raquel P. Deering, PhD, Sara Hamon, PhD, Gavin Thurston, PhD, Andrew J. Murphy, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Max S. Topp, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 762.
https://doi.org/10.1182/blood-2019-122451
Published: 2019
Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Nitin Jain, MD, Koji Sasaki, MD, Rita Khouri, Naval G. Daver, MD, Naveen Pemmaraju, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Yesid Alvarado, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Musa E. Yilmaz, MD, Gautam M. Borthakur, MD, Jan A. Burger, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSc, Alessandra Ferrajoli, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Rebecca Garris, MSc, Marygrace Ward, RDC, Binru Huang, RDC, Corabelle Encarnacion, RDC, Christopher Loiselle, BS, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 823.
https://doi.org/10.1182/blood-2019-125136
Published: 2019
Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Tait D. Shanafelt, MD, Victoria Wang, Neil E. Kay, MD, Curtis A. Hanson, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD MS, Diane F Jelinek, PhD, Esteban Braggio, PhD, Jose F. Leis, MD PhD, Cong Christina Zhang, Steven Coutre, MD, Paul M. Barr, MD, Amanda F Cashen, MD, Anthony R. Mato, MD MSCE, Avina Singh, MD, Michael P. Mullane, MD, Richard F. Little, MD MPH, Harry P. Erba, MD PhD, Richard M. Stone, MD, Mark Litzow, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 33.
https://doi.org/10.1182/blood-2019-126824
Published: 2019
Journal Articles

Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Paul M. Barr, MD, Alessandra Tedeschi, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Jennifer Woyach, MD, John C. Byrd, MD, Paolo Ghia, MD PhD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Sandra Dai, PhD MS, Carlos Amaya-Chanaga, MD, James P. Dean, MD PhD, Susan M. o'Brien, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3054.
https://doi.org/10.1182/blood-2019-123327
Published: 2019